<DOC>
	<DOCNO>NCT01581736</DOCNO>
	<brief_summary>This protocol conduct determine mechanism responsible insulin resistance , obesity type 2 diabetes .</brief_summary>
	<brief_title>Molecular Regulation Muscle Glucose Metabolism</brief_title>
	<detailed_description>This protocol involve performance hyperinsulinemic euglycemic clamp 2 muscle biopsy exercise study muscle biopsy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Subjects must able communicate meaningfully investigator must legally competent provide write informed consent . 2 . Subjects may either sex , age describe protocol . Female subject must nonlactating must either least two year postmenopausal , ( diabetic obese ) use adequate contraceptive precaution ( i.e . oral contraceptive , approve hormonal implant , intrauterine device , diaphragm spermicide , condom spermicide ) , surgically sterilize ( i.e . bilateral tubal ligation , bilateral oophorectomy ) . Female patient ( except patient undergone hysterectomy bilateral oophorectomy ) eligible negative pregnancy test throughout study period . 3 . Subjects must range age describe specific protocol . 4 . All nondiabetic subject must normal oral glucose tolerance . 5 . Subjects must follow laboratory value : Hematocrit ≥ 35 vol % Serum creatinine ≤ 1.6 mg/dl AST ( SGOT ) &lt; 2 time upper limit normal ALT ( SGPT ) &lt; 2 time upper limit normal Alkaline phosphatase &lt; 2 time upper limit normal Triglycerides &lt; 150 mg/dl . PT 11.7 14.3 ( During Liposyn/heparin infusion , PT determine insure &lt; 1.52.0 time normal value . ) PTT 23.037.0 . 1 . Subjects must receive follow medication : thiazide furosemide diuretic , betablockers , chronic medication know adverse effect glucose tolerance level unless patient stable dose agent past three month entry study . Subjects may take stable dose estrogens hormonal replacement therapy , subject agent prior three month . Subjects take systemic glucocorticoid exclude . 2 . Subjects history clinically significant heart disease ( New York Heart Classification great grade II ; nonspecific STT wave change EKG ) , peripheral vascular disease ( history claudication ) , pulmonary disease ( dyspnea exertion one flight le ; abnormal breath sound auscultation ) study . 3 . Recent systemic pulmonary embolus , untreated highrisk proliferative retinopathy , recent retinal hemorrhage , uncontrolled hypertension , systolic BP &gt; 180 , diastolic BP &gt; 105 , autonomic neuropathy , rest heart rate &gt; 100 , electrolyte abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>insulin resistance</keyword>
	<keyword>mitochondrion</keyword>
</DOC>